

Not for release to US wire services or distribution in the United States

ASX RELEASE

**SPP shares to be allotted today
Trading of SPP shares to commence on 19 May 2020**

Wellington, NZ, 18th May 2020: Following the successful completion of its share purchase plan (**SPP**) to eligible shareholders, raising a total of A\$9 million, [Volpara Health Technologies Limited](#) (**Volpara**; ASX:VHT) is pleased to confirm that a total of 6,922,595 new shares have been settled and will be allotted today to participants in the SPP.

The SPP was announced to the ASX on 28 April 2020 following the successful completion of Volpara's A\$28 million institutional share (**Placement**). The SPP allowed eligible shareholders the ability to subscribe for up to A\$30,000 of new fully paid ordinary shares in Volpara (**New Shares**) at an issue price of A\$1.30 (representing a 10.3% discount to the price of Volpara shares on ASX on 16 April 2020 (the last trading day prior to announcing the Placement and SPP)).

The SPP closed at 5.00pm (Sydney time) on Monday, 11 May 2020 with applications exceeding A\$11 million, in excess of the A\$7 million that the Company aimed to raise under the SPP. As a result, applications were scaled back at the discretion of the Company, predominantly on a pro rata basis but also taking into account, in certain cases, the size of the respective shareholding relative to the application amount. Together with the Placement, the Company has raised a total of \$37 million under its capital raising. The funds raised under the Placement and SPP (net of costs) will be used for general working capital purposes and to fund potential future acquisition opportunities.

Holding statements for the New Shares issued under the SPP will be despatched on Tuesday, 19 May 2020, with trading in the New Shares on ASX on a normal settlement basis commencing on the same day.

Authorisation and additional Information

This announcement was authorised by a sub-committee of the Board.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Communications
kwilliamson@we-worldwide.com
t: +61 3 9866 4722



About Volpara Health Technologies Limited

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS Systems, Inc., a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

Further information about Volpara can be found at <https://volparasolutions.com>

Not for release to US wire services

*This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 (as amended, the **US Securities Act**) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.*